CHMP backs ticagrelor, Tasigna

The European Medicines Agency's CHMP issued several opinions on Friday, including recommending approval of Brilique ticagrelor from AstraZeneca plc (LSE:AZN; NYSE:AZN) to prevent atherothrombotic events in acute coronary syndrome (ACS) patients. The reversible adenosine diphosphate (ADP) receptor (P2Y12) antagonist is under FDA review as Brilinta, with a PDUFA date of Dec. 16. ...